Why Heparin is Given in Myocardial Infarction
Heparin is administered in acute MI to prevent coronary rethrombosis, reduce reinfarction and death, and prevent systemic thromboembolism—always in combination with aspirin, never as monotherapy. 1
Pathophysiologic Rationale
Coronary thrombosis drives the pathogenesis of acute MI, and the risk of rethrombosis remains critically high immediately after vessel opening (whether spontaneous or thrombolysis-induced). Blood flowing through the newly opened artery encounters thrombin bound to fibrin in residual thrombus, creating a prothrombotic environment. Heparin ameliorates these thrombotic manifestations by inhibiting thrombin activity and preventing recurrent coronary thrombosis. 1
Clinical Evidence for Efficacy
In Unstable Angina/Non-STEMI
When combined with aspirin, heparin reduces short-term cardiovascular death and MI by approximately 30% compared to aspirin alone. In landmark trials, MI incidence dropped from 11.9% (placebo) to 0.8% (heparin alone) and 1.6% (heparin plus aspirin). 1
With Thrombolytic Therapy
The evidence diverges based on the thrombolytic agent used:
- With tissue plasminogen activator (t-PA): Intravenous heparin is essential and prevents early recurrent coronary thrombosis 2, 3
- With streptokinase: The benefit is less clear; subcutaneous heparin (12,500 U twice daily) showed mortality benefit in some trials, but this dosing fails to achieve therapeutic anticoagulation within 24 hours in most patients 4, 5, 3
Critical dosing distinction: Subcutaneous heparin at standard doses does NOT provide adequate anticoagulation in the first 24 hours when most rethrombosis occurs. 4
Recommended Dosing Protocol
According to AHA guidelines 1:
- For acute MI without thrombolytics: 5,000 U IV bolus followed by 32,000 U per 24 hours IV infusion, adjusted to maintain aPTT in therapeutic range (1.5-2.0 times control)
- For acute MI after thrombolytic therapy: 5,000 U IV bolus followed by 24,000 U per 24 hours (lower dose due to increased bleeding risk with combined therapy)
- Duration: Typically 5-10 days, though longer courses may be appropriate for non-Q-wave MI 6
Critical Safety Monitoring
Heparin resistance is frequently encountered in MI patients 7, requiring close monitoring of coagulation tests and possible dose adjustment based on anti-Factor Xa levels.
Mandatory monitoring includes:
- Baseline platelet count before initiating heparin
- Platelet counts on Day 5 and periodically thereafter (HIT occurs in up to 9.56% of ACS patients, with higher risk in STEMI/NSTEMI versus unstable angina) 8
- aPTT monitoring to maintain therapeutic range (55-70 seconds optimal to prevent bleeding while maintaining efficacy) 3
- Hematocrit and occult blood in stool throughout therapy 7
Key complications to watch:
- Heparin-induced thrombocytopenia (HIT): Occurs 2-20 days after initiation; if platelets drop below 100,000/mm³ or thrombosis develops, immediately discontinue heparin and switch to alternative anticoagulant 7
- Major bleeding: Risk increases when combined with thrombolytics or GP IIb/IIIa inhibitors, necessitating dose reduction 1
Modern Context and Alternatives
While heparin remains FDA-indicated for acute MI 7, bivalirudin has emerged as a safer alternative with significantly lower bleeding rates (mucosal bleeding 2% vs 6%, puncture site 3% vs 8%) while maintaining comparable efficacy in preventing major adverse cardiovascular events 9. However, some meta-analyses show bivalirudin associated with higher rates of MI, urgent revascularization, and stent thrombosis compared to unfractionated heparin plus GP IIb/IIIa inhibitors 10.
Clinical Pitfalls to Avoid
- Never use heparin as monotherapy—always combine with aspirin 1
- Avoid subcutaneous dosing in acute phase—it fails to achieve therapeutic levels when rethrombosis risk is highest 4
- Don't use full-dose heparin with thrombolytics—reduce to 24,000 U/24h to minimize bleeding 1
- Monitor for HIT especially in STEMI patients presenting >12 hours after symptom onset—they have highest risk 8
- Maintain aPTT 55-70 seconds—higher levels increase bleeding without improving outcomes 3